The Austrian Society for Bone and Mineral Research routinely publishes 
evidence-based guidelines for the treatment of postmenopausal osteoporosis. The 
fully human monoclonal antibody denosumab (Prolia(®)) has been recently approved 
by the European Medical Agency (EMEA) and the Food and Drug Administration (FDA) 
for the treatment of postmenopausal osteoporosis. Denosumab has been shown to 
reduce vertebral, non-vertebral,and hip-fracture risk effectively. Together with 
alendronate, risedronate, zoledronate, ibandronate, strontium ranelate, and 
raloxifene, denosumab constitutes an effective option in the treatment of 
postmenopausal osteoporosis.